(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in the journal “Frontiers in Immunology”. Through activation of ChemR23, OSE-230 reprograms tumor-associated macrophage cells. The ChemR23 receptor strongly controls the macrophage phenotype and its activation by OSE-230 results in significant remodeling of the immune tumor microenvironment.
“We are very pleased with this publication of OSE-230 in ‘Frontiers in Immunology’, a leading journal in its field which publishes major discoveries in immunology”, declared Aurore Morello, Director of Research & Development of OSE Immunotherapeutics. “These data make OSE-230 a first-in-class candidate for more advanced preclinical studies and pave the way for many chronic inflammatory disease indications, thanks to the product’s significant strengths over immunosuppressive treatments.”
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
